Borja del Pozo-Cruz1, Rosa M Alfonso-Rosa2, Jesus del Pozo-Cruz2, Borja Sañudo2, Michael E Rogers3. 1. Department of Sport and Exercise Science, University of Auckland, Auckland, New Zealand. Electronic address: b.delpozocruz@auckland.ac.nz. 2. Department of Physical Education and Sports, University of Seville, Seville, 5, Spain. 3. Department of Human Performance Studies, Wichita State University, Wichita, KS, 6, USA.
Abstract
OBJECTIVE: To test the feasibility, safety and effectiveness of a 12-wk whole body vibration (WBV) intervention on glycemic control, lipid-related cardiovascular risk factors and functional capacity among type 2 diabetes mellitus (T2DM) patients in a primary care context. METHODS:Fifty non-insulin dependent T2DM patients were randomized 1:1 to an intervention group that, in addition to standard care, received a 12-wk WBV intervention, and a control group receiving only standard care (from February 2012 through May 2012). Outcomes, including glycated hemoglobin (HbA1c), fasting blood glucose, lipid-related cardiovascular risk factors (i.e., cholesterol, triglycerides, lipoproteins, LDL/HDL and atherogenic index) and functional capacity were measured at baseline and after the 12-wk intervention. RESULTS: After intervention, there was a reduction in HbA1c and fasting blood glucose when compared to the control group, with a mean difference in change scores between groups of -0.55% (95% CI -0.15 to -0.76) and -33.95 mm/dl (95% CI -51.38 to -3.47), respectively. Similarly, most lipid-related cardiovascular risk factors (i.e., cholesterol, triglycerides and atherogenic index) were also reduced (p<0.05). CONCLUSION: A 12-wk WBV intervention in a primary care context is feasible, safe and effective in improving glycemic profile, lipid-related cardiovascular risk factors and functional capacity among T2DM patients. TRIAL NUMBER: ACTRN12613000021774.
RCT Entities:
OBJECTIVE: To test the feasibility, safety and effectiveness of a 12-wk whole body vibration (WBV) intervention on glycemic control, lipid-related cardiovascular risk factors and functional capacity among type 2 diabetes mellitus (T2DM) patients in a primary care context. METHODS: Fifty non-insulin dependent T2DM patients were randomized 1:1 to an intervention group that, in addition to standard care, received a 12-wk WBV intervention, and a control group receiving only standard care (from February 2012 through May 2012). Outcomes, including glycated hemoglobin (HbA1c), fasting blood glucose, lipid-related cardiovascular risk factors (i.e., cholesterol, triglycerides, lipoproteins, LDL/HDL and atherogenic index) and functional capacity were measured at baseline and after the 12-wk intervention. RESULTS: After intervention, there was a reduction in HbA1c and fasting blood glucose when compared to the control group, with a mean difference in change scores between groups of -0.55% (95% CI -0.15 to -0.76) and -33.95 mm/dl (95% CI -51.38 to -3.47), respectively. Similarly, most lipid-related cardiovascular risk factors (i.e., cholesterol, triglycerides and atherogenic index) were also reduced (p<0.05). CONCLUSION: A 12-wk WBV intervention in a primary care context is feasible, safe and effective in improving glycemic profile, lipid-related cardiovascular risk factors and functional capacity among T2DM patients. TRIAL NUMBER: ACTRN12613000021774.
Authors: Meghan E McGee-Lawrence; Karl H Wenger; Sudipta Misra; Catherine L Davis; Norman K Pollock; Mohammed Elsalanty; Kehong Ding; Carlos M Isales; Mark W Hamrick; Marlena Wosiski-Kuhn; Phonepasong Arounleut; Mark P Mattson; Roy G Cutler; Jack C Yu; Alexis M Stranahan Journal: Endocrinology Date: 2017-05-01 Impact factor: 4.736
Authors: Maíra Florentino Pessoa; Helga C Muniz de Souza; Alanna P Vasconcelos da Silva; Rafaela Dos Santos Clemente; Daniella Cunha Brandão; Armèle Dornelas de Andrade Journal: Rehabil Res Pract Date: 2018-06-05
Authors: Caroline C Robinson; Rodrigo P G Barreto; Graciele Sbruzzi; Rodrigo D M Plentz Journal: Braz J Phys Ther Date: 2015-11-17 Impact factor: 3.377
Authors: L Seefried; F Genest; N Luksche; M Schneider; G Fazeli; M Brandl; U Bahner; A A Heidland Journal: J Musculoskelet Neuronal Interact Date: 2017-12-01 Impact factor: 2.041